**EXHIBIT 10.28**

**FIRST      AMENDMENT TO THE MANUFACTURING AND SUPPLY AGREEMENT**

**DATED      DECEMBER 7 2003**

**BACKGROUND**

| 1. | **Installation                of 4th Bioreactor**.                Lonza shall add a fourth bioreactor and associated equipment to the                Lonza                Facility. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | **Validation                of 4th Bioreactor**.                Following installation of such fourth bioreactor, Lonza shall use                its                Commercially Reasonable Best Efforts to validate such reactor for                use with                the Manufacturing Process and in order to commence Commercial Production                of Bulk Drug (i.e., commencement of the first Commerical Run) with                such                fourth bioreactor, as soon as is reasonably practicable, but in any                event                no later than **[*]**Campaign,                **[*];**provided,                in no event shall Lonza take any action that would impair or delay                its                obligation to conduct Commercial Production of Bulk Drug in the existing                reactors at the Lonza Facility and deliver Bulk Drug in the amounts                and                time frame specified in the Agreement. Lonza shall notify Genentech                in                writing promptly upon Lonza becoming aware of any such activity that                may                result in such impairment or delay, and shall not initiate any such                activity without obtaining Genentech’s prior written review and                approval. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3. | **Qualification                Runs on 4th Bioreactor**.                Without limiting the foregoing, Lonza shall use Commercially Reasonable                Best Efforts to perform **[*]**Qualification                Runs to produce at least **[*]**on                such fourth bioreactor by no later than **[*]**in                this Section of the Amendment; provided, Genentech shall have no                obligation to pay Lonza for more than **[*].**Subject                to the foregoing, for each **[*]**manufactured                on such fourth bioreactor in conformance with cGMP, the Bulk Drug                Specifications, the Target Yield, and the warranties in Section 7.1,                Genentech shall pay Lonza an amount equal to **[*].**Such                amounts shall be the Purchase Price for such Qualifications Batches.                Genentech may make whatever further uses of such Batches, including                without limitation, any Product therefrom, as it shall determine                is                appropriate. Lonza shall use Commercially Reasonable Best Efforts                to                provide all the required documentation to Genentech to support the                sBLA                filing for the fourth bioreactor by no later than the **[*]** |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4. | **Commercial                Production on 4th Bioreactor**.                Following the completion at commercial scale of at least **[*]**on                such fourth bioreactor that complies with cGMP, the Bulk Drug                Specifications, the Target Yield, and the warranties in Section 7.1,                and                execution and delivery by Lonza of the related Certificates of Compliance                and Certificates of Testing, Genentech shall have the right to provide                written notice to Lonza to commence, and following receipt of such                notice                Lonza shall commence, Commercial Production of Bulk Drug with such                fourth                bioreactor under this Agreement. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5. | **Adjustments                to Annual Minimums following Commencement of Commercial Production                on the                4th Bioreactor**.                Concurrent with the Calendar Quarter in which Commercial Production                of                Bulk Drug on such fourth bioreactor commences, the Campaign Minimum                Runs                and Successful Commercial Batches for such Calendar Quarter and each                Calendar Quarter thereafter, as detailed in Exhibit A of the Agreement,                shall be amended to **[*]**                (i.e., as of the effective date of this Amendment**,                [*]** |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6. | **Rescheduling                of the [*] Campaigns**.                Notwithstanding the Campaign, Campaign Minimum and Campaign Minimum                Run                schedule listed on Exhibit A: |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**[*]**
**[*]**
**[*]**
**[*]      **
**[*]      **
**[*]**

**[*]**
**[*]      **
**[*]**
**[*]      **
** **
**[*]      **
**[*]      **
**[*]      **
**[*]**

----

**[*]      **
**[*]      **
**[*]      **
**[*]      **
**[*]      **

| 7. | **Cross-Contamination**.                In order to minimize the risk of cross-contamination of Product with                another product at the Lonza Facility, during the period of time                that                Lonza is processing any Bulk Drug in any of the existing bioreactors                at                the Lonza Facility, Lonza shall not introduce or process any other                product                in the fourth bioreactor after the process piping of such fourth                bioreactor is connected to the existing                bioreactors. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8 | **Genentech                [*] 4th Bioreactor**.** **With                respect to **[*.]** |
|---|---------------------------------------------------------------------------------------------------|

| 9. | All                terms and conditions of the Agreement not modified by this Amendment                shall                continue in full force and effect. All capitalized terms not otherwise                defined herein shall have the same definition as in the                Agreement. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| GENENTECH,                INC.       |                                                     |
|--------------------------------------|----------------------------------------------------------|
|                                 |                                                     |   |
| By:                                  | /s/                DAVID EBERSMAN                        |   |
|                                 |                                                     |   |
| Name:                                | David                Ebersman                            |   |
| Title:                               | Senior                Vice President, Finance            |   |
|                                 |                                                     |   |
|                                 |                                                     |   |
| By:                                  | /s/                PAT YANG                              |   |
|                                 |                                                     |   |
| Name:                                | Pat                Yang                                  |   |
| Title:                               | Senior                Vice President, Product Operations |   |
|                                 |                                                     |   |
|                                 |                                                     |   |
| LONZA                BIOLOGICS, INC. |                                                     |
|                                 |                                                     |   |
| By:                                  | /s/                GERHARD KLEMENT                       |   |
|                                 |                                                     |   |
| Name:                                | Gerhard                Klement                           |   |
| Title:                               | Chief                Operating Officer                   |   |
|                                 |                                                     |   |
| LONZA                BIOLOGICS, PLC  |                                                     |
|                                 |                                                     |   |
| By:                                  | /s/                GERHARD KLEMENT                       |   |
|                                 |                                                     |   |
| Name:                                | Gerhard                Klement                           |   |
| Title:                               | Chief                Operating Officer                   |   |

----